Yesterday in JAMA, authors printed promising outcomes from a part 3 trial on the security and immunogenicity of a mixed seasonal flu and COVID vaccine, Moderna’s mRNA-1083, in adults 50 and older.
The mRNA-1083 vaccine includes elements of mRNA-1010, Moderna’s vaccine candidate for seasonal influenza, and mRNA-1283, Moderna’s next-generation COVID-19 vaccine candidate focusing on Omicron XBB.1.5.
In whole, 8,015 individuals had been enrolled within the part 3 trial and vaccinated. Members had been cut up into two age cohorts (65 years and older and 50 to 64 years) who had been randomly assigned to obtain mRNA-1083 plus placebo, or coadministered licensed quadrivalent seasonal influenza (≥65 years: high-dose quadrivalent inactivated influenza vaccine [HD-IIV4]; 50 to 64 years: standard-dose IIV4 [SD-IIV4]) and COVID-19 (all ages: mRNA-1273) vaccines.
General, the mixed vaccine was discovered to be non-inferior to plain seasonal influenza and COVID-19 vaccines.
Greater immune response in mixed vaccine
For all ages, mRNA-1083, the mixed vaccine, elicited greater immune responses than the standard-dose flu vaccine given to these 50 to 64 years, and for all influenza strains within the high-dose class. For all ages, the mixed vaccine elicited greater immune response in opposition to SARS-CoV-2.
Although no severe security considerations had been seen, the mixed vaccine did have extra non-serious adversarial reactions. The adversarial reactions had been numerically greater in frequency and severity after mRNA-1083 vaccination than comparators in each age cohorts, the authors stated.
The mRNA platform to develop the mixed vaccine has quite a few benefits, the authors wrote, together with avoidance of egg adaptation–associated modifications, in addition to the breadth of immunity and T-cell responses for the influenza element (mRNA-1010).
Mixture vaccines have the potential to cut back the burden of respiratory viruses on well being methods and pharmacies,
In an announcement from Moderna on the preliminary outcomes of this trial printed final summer season, Moderna CEO Stephane Bancel, MBA, MS, stated, “Mixture vaccines have the potential to cut back the burden of respiratory viruses on well being methods and pharmacies, in addition to supply folks extra handy vaccination choices that might enhance compliance and supply stronger safety from seasonal diseases.”
